January 26, 2015 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of BioScrip Inc (NASDAQ:BIOS) shares was announced over potential breaches of fiduciary duties by certain officers and directors at BioScrip Inc .

The investigation by a law firm concerns whether certain BioScrip officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

On September 23, 2013, BioScrip Inc disclosed that the Company received a civil investigative demand issued by the United States Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company's legacy specialty pharmacy division.

On September 30, 2013, a lawsuit was filed against BioScrip over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that BioScrip Inc improperly distributed the product Exjade through its specialty pharmacy operations, that BioScrip Inc was in violation of certain federal and state laws and regulations, and that as a result of the foregoing BioScrip's statements were materially false and misleading at all relevant times.

BioScrip Inc reported that its annual Total Revenue rose from $662.64 million in 2012 to $842.20 million in 2013 while its Net Income of $64.71 million in 2012 declined to a Net Loss of $69.65 million in 2013. Shares of BioScrip Inc (NASDAQ:BIOS) declined from $16.55 per share in August 2013 to as low as $5.69 per share in November 2014.